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Abstract
Purpose: Systemic treatment with an anti-ICAM-2
monoclonal antibody (mAb; EOL4G8) eradicates certain
established mouse tumors through a mechanism dependent
on the potentiation of a CTL-mediated response. However,
well-established tumors derived from the MC38 colon car-
cinoma cell line were largely refractory to this treatment as
well as to intratumor injection of a recombinant adenovirus
encoding interleukin-12 (IL-12; AdCMVIL-12). We sought
to design combined therapy strategies with AdCMVIL-12
plus anti-ICAM-2 mAbs and to identify their mechanism of
action.
Experimental Design: Analysis of antitumor and toxic
effects were performed with C57BL/6 mice bearing estab-
lished MC38 tumors. Anti-ovalbumin T-cell receptor trans-
genic mice and tumors transfected with this antigen were
used for in vitro and in vivo studies on activation-induced cell
death (AICD) of CD8 T cells.
Results: Combined treatment with various systemic
doses of EOL4G8 mAb plus intratumor injection of AdC-
MVIL-12 induced complete regression of MC38 tumors
treated 7 days after implantation. Unfortunately, most of
such mice succumbed to a systemic inflammatory syndrome
that could be prevented if IFN- activity were neutralized
once tumors had been rejected. Importantly, dose reduction
of EOL4G8 mAb opened a therapeutic window (complete
cure of 9 of 18 cases without toxicity). We also show that
ICAM-2 ligation by EOL4G8 mAb on activated CTLs pre-
vents AICD, thus extending IFN- production.
Conclusions: Combination of intratumor gene transfer
of IL-12 and systemic anti-ICAM-2 mAb display synergistic
therapeutic and toxic effects. CTL life extension resulting
from AICD inhibition by anti-ICAM-2 mAbs is the plausible
mechanism of action.
Introduction
ICAM-2 (CD102) is a glycosylated surface adhesion pro-
tein (1–3) expressed on endothelial cells and activated lympho-
cytes (2). Two ligands have been identified for this molecule:
the leukocyte integrin LFA-1 (4) and the dendritic-cell-
restricted C-type lectin DC-SIGN (CD209; Ref. 5).
In a recent study, we found that systemic administration of
a mAb3 specific for ICAM-2 (EOL4G8) was able to induce
complete regression of tumors derived from the CT26 colon
carcinoma cell line (6). Such tumor regression is dependent on
a functional immune system and correlates with the induction of
tumor-specific cytotoxicity mediated by CD8 T cells (6). The
intrinsic mechanism underlying this antitumor activity is un-
known, although it was found that EOL4G8 mAb was able to
increase ICAM-2 binding to DC-SIGN (6). However, the rela-
tionship of this adhesion phenomenon to tumor immunity re-
mains elusive. Recent evidence showed that cross-linking of
human ICAM-2 was able to prevent the apoptosis of ICAM-2-
transfected cells as well as in T cell lines (7). In those cellular
systems, ICAM-2 binds ezrin in such a fashion that it becomes
phosphorylated and recruits PI3K to the inner leaf of the plasma
membrane, resulting in the elicitation of an antiapoptotic sig-
naling cascade mediated by AKT (protein kinase B) phospho-
rylation and subsequent regulation of a number of substrates that
result in the inhibition of BAD (7). Apoptosis is known to
control clonal expansion in T cells to keep the immune response
under control (8). AICD is a frequent outcome of T-lymphocyte
activation through TCRs (8). Prominent roles played by FAS/
FAS-L interactions (9), TNFR-II (10), IL-2 (11), IFN- (12) and
the intracellular BCL-homologue BIM (13) have been described
in this complex mechanism of immune regulation. Interference
with AICD could be therapeutically useful to enhance desired
immune responses.
IL-12 (14) is a potent antitumor agent (15) with a multi-
layered mechanism of action that includes potentiation of CTL
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responses, increases in NK activity (14), proinflammatory
changes in tumor tissue (16, 17) and antiangiogenic effects (18).
These actions of IL-12 are mainly mediated by its property of
inducing IFN- release from T cells in an antigen-independent
fashion (14). IFN- is also the main mediator of the severe
systemic inflammatory shock that results from IL-12 overdose
(19–22). Tumor gene transfer of IL-12 genes has been used to
treat tumors with the idea of confining production of the cyto-
kine to malignant tissue, thus limiting collateral damage in-
flicted by IFN-. Intratumor gene transfer of IL-12 with adeno-
virus is a safe and efficacious approach against rodent
transplanted tumors (23–25). Many strategies have been ex-
plored to increase efficacy including combinations with other
transgenes (25–28) and with agonistic anti-CD137 (4–1BB)
mAbs (29, 30). Those anti-CD137 mAbs mediate antitumor
effects (31) by enhancing a weak CTL response as a result of
mAb interactions with CTLs (32), NK cells (33), and maturing
dendritic cells (34).
In this study, we have found that (a) EOL4G8 anti-ICAM-2
mAb synergistically enhances the antitumor effects of intratu-
mor gene transfer of IL-12, (b) this combination may result in
lethal IFN--related toxicity, and (c) ICAM-2 ligation by spe-
cific anti-ICAM-2 mAbs on activated CTLs can inhibit AICD
both in vitro and in vivo, thus extending the viable period of
IFN- production. These findings provide a rationale for the
efficacy and toxicity of this treatment combination.
Materials and Methods
Cell Lines, mAbs, and Peptides. MC38 colon carci-
noma cells (35) were cultured in DMEM10% FCS (Life
technologies SA., Barcelona. Spain), and CTLL-2 immortalized
T cells (American Type Culture Collection, Manassas, VA),
which are absolutely dependent for growth on IL-2, were cul-
tured in RPMI 1640 supplemented with 10 IU/ml human re-
combinant IL-2 (Chiron, Emeryville, CA) and 10% (v/v) FCS
(Life Technologies, Inc.). EG.7 is a EL-4 lymphoma variant that
has been transfected with an expression cassette to express
full-length ovalbumin, which was obtained as a kind gift from
Dr. M. Bevan (University of Washington. Seattle. WA; Ref. 36).
EG.7 cells were cultured in DMEM10%FCS.
EOL4G8 mAb (rat IgG2b) was obtained and purified by
affinity chromatography on Sepharose-protein G columns (Am-
ersham-Pharmacia Biotech, Uppsala. Sweden) as described pre-
viously (6). The anti-CD137 mAb (rat IgG2a) called 2A was
kindly provided by Dr. Lieping Chen (Mayo Clinic, Rochester,
MN; Ref. 37). Purified or fluorochrome-tagged anti-CD3, anti-
CD4, anti-CD8, anti-CD69, and 3C4 anti-ICAM-2 mAbs were
from PharMingen (San Diego, CA). Polyclonal rat IgG was
purchased from Sigma (Alcobendas, Madrid, Spain).
Peptide SIINFEKL (OVA 257–264) was synthesized man-
ually in a multiple peptide synthesizer using FMOC [N-(9-
fluorenyl)methoxycarbonyl] chemistry. Ninhydrin test of Kaiser
was used to monitor every step. At the end of the synthesis they
were cleaved and deprotected with trifluoroacetic acid and
washed with diethyl ether. Purity of the peptides was always
above 90% as assessed by high-performance liquid chromatog-
raphy.
Recombinant Adenoviruses. Recombinant adenovi-
ruses carrying the p40 and p35 genes of murine IL-12 (AdCM-
VIL-12) or -galactosidase (AdCMVlacZ) under the control of
the cytomegalovirus (CMV) promoter have been described pre-
viously (38, 39). Adenoviruses were purified by double cesium
chloride ultracentrifugation and extensively dialyzed against 10
mM Tris/1 mM MgCl2 before being stored at 80°C in the
presence of 10% (v/v) glycerol. Titration was made by plaque
assay (40).
Mice. Six-to-8-week-old C57BL/6 female mice were
purchased from Harlan (Barcelona, Spain) and housed under
specific-pathogen-free conditions in the University of Navarra.
A breeding pair of OT-I transgenic mice in C57BL/6 back-
ground were obtained from Dr. Balbino Alarco´n (Centro de
Biologı´a Molecular Severo Ochoa, Madrid, Spain) with permis-
sion from Dr. Francis R. Carbone (WEHI, Parkville, Victoria,
Australia; 41) and were bred in our animal facility. All of the
animal handling and in vivo experiments were performed fol-
lowing institutional guidelines and have been approved by the
animal facility ethical committee.
In Vivo Tumor Experiments. Five  105 MC38 cells
were injected s.c. in the shaved right flank of syngeneic mice
with a 280-G syringe (6). Tumor sizes were followed with a
precision caliper and recorded at least weekly (most often every
3 days). The general well-being of the mice was recorded in
comparison with control groups by observation, weighing, esti-
mation of the amount of water drunk per cage, and watching the
escaping response to stimulation by gentle poking with a blunt
pencil.
To assess AICD in vivo, we injected 5  105 EG.7 cells in
HBSS (100 l/injection) s.c. in both flanks of OT-I transgenic
mice and treated them i.p. with 100 g of EOL4G8 or control
antibody 4 days later. On day 7, draining lymph nodes were
harvested from euthanized mice, and a cell suspension was
obtained for flow cytometry studies.
FACS Staining and ELISA. Immunostaining with anti-
bodies has been described previously (42). FITC-annexin V
staining was performed with a commercial kit (PharMingen) in
accordance with the manufacturer’s instructions. Samples were
processed with a FACScalibur instrument (Becton-Dickinson,
Madrid, Spain), and results were analyzed with CellQuest soft-
ware.
Mytomicin-C was commercially purchased from Sigma
and was used at 50 g/ml during 2 h at 37°C to arrest the
proliferation of MC38 cells that were washed three times in
DMEM before setting 4-day cocultures with splenocytes.
IFN- ELISAs were from PharMingen and were performed
according to the manufacturer’s instructions.
Results
Anti-ICAM-2 mAb AdCMVIL-12 Combined Effects.
Our published experiments (6) showed that i.p. treatment with
two doses of 100 g of EOL4G8 anti-ICAM-2 mAb could cure
a fraction of tumors derived from s.c. inoculation of MC38
colon cancer cells in syngeneic mice, if given when tumor
nodules were still unpalpable (as early as day 0 to day 4 after
tumor cell inoculation). By contrast, if treatment onset was
postponed to day 7 after tumor cell injection, no curative effects
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were seen, and tumors progressed to kill the mouse, albeit with
some delay if compared with control antibody-treated mice (6).
In experiments shown in Table 1, we confirmed those treatment
failures, because in a group of five mice that were treated with
EOL4G8 mAb i.p on days 7, 9, and 11 after s.c. injection of
MC38 cells, none of the tumors was rejected.
Our group has demonstrated the effectiveness of gene
therapy strategies based on intratumor injections with an ade-
novirus encoding IL-12 (AdCMVIL-12) against a number of
rodent tumors. However, MC38-derived tumors are highly re-
sistant to treatment with doses of 108 to 109 pfu of AdCM-
VIL-12 (Table 1). Our hypothesis was that combined treatment
with EOL4G8 mAb and AdCMVIL-12 could result in therapeu-
tic activity against well-established MC38 tumors. As can be
seen in Table 1, one dose of AdCMVIL-12 (108 pfu) given on
day 7 (mean tumor diameter ranging from 4 to 7 mm) plus three
i.p. doses of EOL4G8 mAb of 150 g i.p. given every other day
after day 7 resulted in complete regression in 10 of 12 cases,
whereas AdCMVIL-12 plus an identical course of control anti-
body resulted in only 2 complete regressions in 12 cases (P 
0.01 by Fishers exact test).
However, starting on day 24–25 after tumor inoculation
(18 days after treatment onset), mice began to look dehydrated,
lost activity, drank and ate poorly, showed altered fur, and, one
day later, became clearly hypothermic. As a result of this
condition, 9 of 12 mice died (Table 1) within 1 week after
symptoms began. Such a syndrome was not seen in any animal
of the control groups. Three moribund mice treated in the same
way as those in the combined group of the second experiment in
Table 1 were euthanized and subjected to postmortem exami-
nations that disclosed congestive lungs and microscopic signs of
edema consistent with acute heart failure. No macroscopic hem-
orrhages or inflamed areas were found, whereas the area of
rejected tumor cells appeared normal without residual malignant
tissue.
IFN- Neutralization Abrogates Toxicity of AdCM-
VIL-12EOL4G8 mAb Treatment. Most of the toxicity
reactions induced by IL-12 are known to be mediated by IFN-
(22). Accordingly, we reasoned that mice given the toxic AdC-
MVIL-12EOL4G8 regime but treated with 300 l of high-
titer ascitic fluid of neutralizing anti-IFN- mAb would be
protected from the toxic shock syndrome (22). We chose day 21
after tumor inoculation for IFN- treatment, when mice were
asymptomatic and most tumors were already macroscopically
rejected or clearly shrinking in size. No toxic deaths took place
in this group of seven mice (Fig. 1a), whereas three mice that
did not receive anti-IFN- died on days 23, 25, and 30 from a
toxic syndrome (data not shown). In the group that had been
treated with EOL4G8AdCMVIL-12 and that received anti-
IFN- treatment, tumors were eradicated in five of seven mice
(Fig. 1a), whereas AdCMVIL-12  control antibody gave rise
to only one tumor cure in seven cases (Fig. 1a). Interestingly, in
the animals that had been treated with AdCMVIL-12 and three
doses of EOL4G8 mAb and that were rescued with neutralizing
anti-IFN- mAb on day 21, the two progressing tumors resulted
from regrowth of an already shrinking tumor and from the
relapse of a tumor nodule that had remained undetectable for 2
weeks after anti-IFN- mAb administration. These results high-
light the activities of IFN- in the toxic reaction and in the
therapeutic activity. Concentrations of IFN- in sera of mice
(n 	 7) that have received 108 pfu AdCMVIL-12 into MC38
tumors, plus a 100-g dose of EOL4G8 i.p., were analyzed 6
days after treatment. Their IFN- concentrations were slightly
higher than those of mice that had received AdCMVIL-12 and
control antibody, although the difference did not reach statistical
significance (Fig. 1b).
Dose Reduction of Anti-ICAM-2 Permits Significant
Efficacy and Eliminates Toxicity. To find a therapeutic win-
dow for the combined treatment with AdCMVIL-12EOL4G8
mAb, we treated a group of 18 mice bearing s.c. MC38 tumors
implanted 7 days earlier. These mice received 108 pfu of AdC-
MVIL-12 intratumorally and a single dose of 150 g of
EOL4G8 i.p. immediately after. Nine of those mice underwent
complete tumor regression (Fig. 2a), whereas another mouse of
the group experienced a transient disappearance of the tumor
nodule. All of the mice in this group were carefully inspected
every day, and no signs of serious illness were detected (they
remained active and steady to stimulation, showing general
well-being). As a control, one group received AdCMVIL-12
intratumorally without antibody and only 1 of 6 rejected its
tumor (Fig. 2b; differences between the AdCMVIL-12 and the
AdCMVIL-12EOL4G8 groups were significant with P 0.01
according to Fishers exact test). In another control group, mice
received an intratumoral injection of the saline vehicle (Fig. 2c).
Table 1 Combined treatment with EOL4G8 mAb i.p. and intratumoral AdCMVIL-12 (IL-12-encoding adenovirus) synergyze both for
therapeutic effects and toxicity
Results from two experiments in which C57BL/6 mice received injections s.c. of 5  105 MC38 cells and were monitored for tumor growth or
regression after receiving three doses of 150 g of EOL4G8 or a control antibody that were given i.p. every other day starting on day 7 after tumor
inoculation combined or not with intratumor injection of a single dose of 108 pfu of AdCMVIL-12 on day 7.
Treatment









4G8 0/5 0/5 NDc ND
Rat IgG 0/5 0/5 ND ND
4G8  Ad IL-12 i.t. 4/5 4/5 6/7 5/7
Rat IgG  Ad IL-12 i.t. 1/5 0/5 1/7 0/7
a Fraction of mice whose tumor nodules became undetectable.
b Fraction of mice that became severely ill between 2 and 3 weeks after treatment and that eventually died from tumor-unrelated causes.
c ND, not done; i.t., intratumoral/intratumorally.
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Parallel experiments demonstrated in vivo gene transduction of
a minority of MC38 cells, mainly in the trajectory of the
injecting needle (not shown). Such in vivo gene transduction of
a MC38 cells was checked with intratumoral injections of Ad-
CMVLacZ encoding for the reporter gene -galactosidase fol-
lowed by X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyr-
anoside) staining of frozen sections.
ICAM-2 Is Expressed on Activated CTLs. We have
previously shown that ICAM-2 expression dramatically increases
in mouse T cells on activation with concanavalin AIL-2 from
almost undetectable levels (6). When splenocytes from OT-I TCR-
transgenic mice, which express a transgenic TCR specific for the
ovalbumin peptide SIINFEKL (OVA257–264) bound to the MHC
class I molecule H2-Kb, were stimulated with the synthetic peptide
at 10 ng/ml, high levels of ICAM-2 (CD102) expression were
detected with the mAbs EOL4G8 and 3C4 (Fig. 3a) on CD8 cells.
Interestingly, freshly isolated lymphocytes from such mice were
virtually negative for EOL4G8 mAb staining both in the CD4 and
CD8 subpopulations (Fig. 3b), indicating that ICAM-2 expression
on T cells can be controlled by antigen stimulation. ICAM-2 is also
expressed on immortalized murine CTL lines like CTLL-2, which
Fig. 1 a, Late in vivo neutralization of IFN- during treatment with
AdCMVIL-2  EOL4G8 anti-ICAM-2 mAb avoids toxicity and per-
mits therapeutic effects. Diameter follow-up of tumor nodules derived
from the s.c. injection of MC38 cells on day 0 that were treated as
indicated on day 7 with 108 pfu of AdCMVIL-12 inside the tumor
nodule. Top graph, mice received three i.p. doses of 150 g of EOL4G8
mAb on days 7, 9, and 11, and one i.p. dose of ascitis fluid containing
a neutralizing anti-IFN- mAb on day 21; middle graph, mice received
a similar course, but with control polyclonal rat antibody and saline;
bottom graph, control group, received an intratumoral (i.t.) volume of
100 l saline buffer on day 7. Not shown, another group of three mice
received a course similar to that in the top panel but with an injection of
polyclonal rat IgG (instead of anti-IFN- treatment) on day 21; all of the
mice died from toxicity between days 24 and 30 after tumor inoculation.
The fraction of tumor-free surviving mice is given in each panel. In b,
IFN- serum concentrations (mean 
 SE) of seven mice per group 6
days after receiving 108 pfu of AdCMVIL-12 i.t.  100 g of EOL4G8
mAb or control antibody i.p.
Fig. 2 Dose reduction of EOL4G8 mAb in combined treatment with
AdCMVIL-12 permits antitumor therapy without lethal toxicity. Exper-
iments are similar to those in Fig. 1, in which the indicated groups of
mice received 108 pfu of AdCMVIL-12 intratumorally (i.t.). Top graph,
mice received an i.p. dose of 150 g of EOL4G8 mAb immediately after
the adenovirusl; middle panel, mice did not receive antibody; bottom
panel, another group of mice were implanted with the same MC38
tumor cells and were left without treatment. Fraction of tumor-free
survival is given in each graph. No signs of toxicity were recorded
during a 3-month close follow up of the animals that rejected their
tumors.
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also expressed activation antigens such as CD137 (4–1BB) and
CD69 (Fig. 3c). In addition, ICAM-2 can be detected on CD8
T-cell blasts from the spleen of mice cured from MC38 tumors
restimulated for 4 days with mytomicin-C-treated MC38 cells plus
10 IU/ml of IL-2, thus indicating that activated CTLs with speci-
ficity for tumor antigens can interact with the anti-ICAM-2 thera-
peutic mAb (Fig. 3d).
ICAM-2 Cross-Linking Inhibits AICD in CD8 T Cells
Both in Vitro and in Vivo. Human ICAM-2 cross-linking has
been reported to transmit apoptosis-inhibitory signals in a num-
ber of cellular systems (7). Apoptosis, a natural outcome of TCR
stimulation, thought to play a major role in the regulation of the
immune response (8). FAS or TNFR ligation on cell surface (9,
10), as well as activation of the proapoptotic molecule BIM,
have been involved in this activity, which is counteracted by
BCL-2 (13). Accordingly, stimulation of OT-I splenocytes with
1 ng/ml OVA257–264 peptide  5 IU/ml IL-2 for 6 days resulted
in 60–70% apoptosis of CD8 transgenic T cells, which were
observed by FACS as cells that were stained both by annexin V
coupled to FITC and by phycoerythrin-tagged anti-CD8 (Fig.
4, a and b). However, if EOL4G8 or 3C4 anti-ICAM-2 mAbs
were applied to the cultured cells at 20 g/ml, then the induction
of apoptosis (measured as annexin V-CD8 cells) was par-
tially inhibited with corresponding higher percentages of viable
CD8 cells that did not bind annexin-V (Fig. 4, a and b). This
effect can also be clearly seen with the number of cellular events
satisfying the electronic gating for living lymphocytes (Fig. 4b).
However, no difference was seen in the rate of proliferation
during the first 3 days of culture as measured with carboxy-
fluorescein succinimidyl ester-labeled lymphocytes or by [3H]-
thymidine uptake into DNA (data not shown; confirming our
previous data in Ref. 6). EOL4G8 mAb also failed to change the
output of IFN- into the tissue culture medium of OVA257–264-
stimulated OT-I splenocytes within the first 48 h after stimula-
tion again confirming our previous data (data not shown and
Ref. 6). By contrast, if IFN- concentrations released into the
culture medium were assessed after 6 days of culture, there was
a 4- to 5-fold increase of the concentration of IFN- in those
cultures containing 10 g/ml of EOL4G8 mAb (Fig. 4c), which
can be interpreted as the result of the extension of the life span
of stimulated CD8 T cells.
To assess whether anti-ICAM-2 mAb were inhibiting
Fig. 3 ICAM-2 is expressed on acti-
vated CD8 CTLs. FACS analysis of im-
munofluorescence staining with the indi-
cated mAbs of OT-I TCR transgenic
splenocytes either after being stimulated
for 72 h with 10 ng/ml of OVA257–264
(a) or freshly isolated (b). In c, a similar
experiment on the CTLL-2 immortalized
T-cell clone is shown. In d, a similar
experiment displaying CD8/ICAM-2
double staining on gated lymphoblasts
(R3) derived from spleens of mice that
had rejected an established MC38 tumor.
Splenocytes were restimulated in vitro
for 4 days with mitomycin-C-pretreated
MC38 cells plus 10 IU/ml of recombinant
IL-2.
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CD8 T-cell apoptosis in vivo, EG.7 tumor cells that express
ovalbumin were injected s.c. into both flanks of OT-I mice. Four
days later, mice were systemically treated with EOL4G8 or with
polyclonal rat antibody as a control. As can be seen in Fig. 5, 3
days after antibody treatment, the draining lymph nodes of
EOL4G8 mAb-treated mice contained less double-stained
(CD8-annexin V) lymphocytes than in those treated with
control antibody (6.6 versus 12.4%). At this time point, the
total number of lymphocytes (mean 
 SE) in draining lymph
nodes was not significantly modified (900,000 
 280,623 in
control antibody group versus 940,000 
 179,315 in
EOL4G8-treated OT-I mice). These data as a whole strongly
indicate that immunotherapy with anti-ICAM-2 antibody in-
hibits the apoptosis of CTLs that have been activated by a
surrogate tumor antigen.
Discussion
This study shows the synergistic effects of systemic anti-
ICAM-2 mAb and IL-12 gene transfer into tumor tissue. Such
synergy was associated not only with a potent therapeutic ac-
tivity but also with a potentially lethal systemic inflammatory
shock. In addition, a plausible mechanistic explanation of the
synergy is provided because cross-linking of ICAM-2 on the
plasma membrane of activated CD8 T cells was able to prevent
AICD, thereby intensifying the total output of IFN- during the
response.
Intratumor IL-12 gene transfer with recombinant adenovi-
rus is efficacious in several rodent tumors (23–25) but could be
toxic above certain doses because of the overproduction of
IFN- (22). Overdosing could also dampen the immune respon-
Fig. 4 Anti-ICAM-2 mAbs in-
hibit activation-induced T-cell
death of CTLs. a and b, FACS
analysis of splenocytes obtained
from OT-I TCR-transgenic mice
stimulated in culture for 6 days
with 10 ng/ml OVA257–264 in the
presence of 20 g/ml of the indi-
cated monoclonal or control anti-
bodies. FACS results are shown as
percentage of double-stained
CD8 lymphocytes with annexin
V-FITC as a marker of apoptotic
cells. In a, percentage of CD8
viable and nonviable cells is pro-
vided. In b, both annexinV staining
and percentage of cell events
within the forward scatter (FSC)
and side scatter (SSC) features of
viable cells are provided (% calcu-
lated from a ratio of viable events:
total events that is also provided in
the indicated figure). c, IFN- con-
centrations assessed by ELISA in
the supernatant of cultures as those
in a and b. Data are representative
of four experiments similarly per-
formed. R1, region 1; R2, region 2.
3551Clinical Cancer Research
 American Association for Cancer Research Copyright © 2003 
 on April 23, 2012clincancerres.aacrjournals.orgDownloaded from 
siveness of the host (43). Certain mouse strains, such as
C57BL/6 are more prone to suffer a lethal syndrome when
treated with AdCMVIL-12 (22). With 108 pfu of AdCMVIL-12
given intratumorally, none of the treated C57BL/6 animals
showed any signs of toxicity, but a very limited tumor efficacy
was observed with this particular tumor model. It should be
noted that a similar dose, if given i.v. instead of intratumorally
to this strain, would be lethal in 6–10 days because of toxic
shock mediated by IFN- (22).
The combination of 108 pfu of AdCMVIL-12 intratumor-
ally and three every-other-day doses of 150 g of EOL4G8
mAb displayed a very dramatic and abrupt antitumor activity
because most MC38-derived tumors were rapidly rejected, and
the mice appeared otherwise healthy. The true synergistic nature
of the therapeutic combination is shown because neither agent
on its own would cause such an effect. However, during the 3rd
week after treatment initiation, a high proportion of mice died
from a condition with symptoms similar to those seen after
overdosing AdCMVIL-12 i.v. (22), but with a much later onset.
The involvement of IFN- in the toxicity was proved by show-
ing that in vivo IFN- neutralization by specific mAbs 2 weeks
after starting this treatment course, when most tumors were
already rejected, prevented lethal toxicity. We observed that two
tumors progressed on IFN- neutralization, one after being
macroscopically undetectable and the other after being already
shrinking its size. Both observations underscore the role of
IFN- in the antitumor activity of IL-12, as has been confirmed
in other immunotherapeutic regimes (15).
A clear therapeutic synergy could be observed also in the
absence of lethal toxicity if only one dose (instead of three
doses) of anti-ICAM-2 antibody were administered i.p. concom-
itantly with AdCMVIL-12 intratumor injection, thus allowing a
dose-dependent therapeutic window. Anti-CD137 agonistic
mAbs (37), which also have potent antitumor properties on their
own (31, 37), have demonstrated synergistic effects with IL-12
intratumoral gene transfer against a colon cancer and in a
metastatic breast cancer model, with no systemic toxicity re-
ported, at least at the doses tested (29, 30).
The idea of combining immunopotentiating mAbs and
IL-12 gene transfer to malignant cells will be important in the
clinic. In support of this point, our results from a recently
finished clinical trial, using escalating intratumoral doses of a
first generation recombinant adenovirus encoding human IL-12
against advanced gastrointestinal tumors, have taught us that the
effect of this gene therapy approach is not efficacious enough by
itself.4 Therefore, combination strategies are needed, and,
among them, those showing truly synergistic complementary
mechanisms of action should be preferred (25). Anti-CD40
antibodies (44) also could be considered an alternative that is
worth testing in combination with AdCMVIL-12, although, in
this case, even the antibody as a single agent caused a lethal
systemic inflammatory syndrome in mice (45). Thus, compar-
ative studies of anti-ICAM-2, anti-CD137, and anti-CD40 in
combination with IL-12 intratumor gene transfer have become
one of our experimental priorities.
AdCMVIL-12 antitumor activity is attributed to CTL gen-
eration (39) and to increases in NK and NK T-cells activity (38),
as well as to antiangiogenic actions (38). The mechanism or
mechanisms of action of the EOL4G8 mAb are less well de-
fined. Involvement of CTLs has been proved, but the intrinsic
mechanism leading to their potentiation is not worked out (6). A
recent publication showed that human ICAM-2, either as natu-
rally expressed or as a transfected molecule in ICAM-2-negative
cells, inhibited apoptosis on overexpression or cross-linking (7).
The effect was studied in detail and was found to involve a chain
of signaling events including ICAM-2-associated ezrin, PI3K,
and AKT (PKB) and the inhibition of BAD (7). The prosurvival
effect was very intense against apoptosis caused by growth
factor deprivation and staurosporin treatment, as well as by FAS
cross-linking.
In our hands, ICAM-2 cross-linking in vitro was capable of
preventing induction of T-cell death by antigen in TCR-trans-
genic T cells stimulated with agonistic peptide and IL-2. More-
over, treatment with anti-ICAM-2 mAb in vivo prevented the
induction of apoptosis of TCR-transgenic CD8 lymphocytes
located at lymph nodes that drain the area in which tumor cells
expressing the relevant antigen had been injected. This antipo-
ptotic effect extended the life span of some of the responding
4 B. Sangro et al., manuscript in preparation.
Fig. 5 In vivo inhibition of activation-induced T-cell death by treatment with anti-ICAM-2 mAbs. Flow cytometry analysis of CD8 lymphocytes
stained with annexin-V obtained from the draining lymph nodes of TCR transgenic OT-I mice harvested 7 days after bilateral s.c. injection of EG.7
cells (OVA transfected EL-4). Groups of four mice each were treated on day 4 with 100 g of either control polyclonal antibody (left) or EOL4G8
mAb (right). Each plot graph represents 104 events from eight pooled inguinal lymph nodes and provides the percentage of double-stained CD8
annexin-V cells. Results are representative of two experiments similarly performed.
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CD8 T cells with the overall result of a higher output of IFN-
into the culture supernatant. Such an antiapoptotic effect was
clearly dissociated from proliferation or early cytokine secre-
tion. Anti-CD137 mAbs have also been described to be primar-
ily antiapoptotic on activated CTLs (46). Activation-induced
T-cell death is conceived as an important homeostatic mecha-
nism to regulate immune responses. A role in AICD has been
described for ligation of the T-cell surface proteins FAS and
TNFR p75 as well as for the cytokines IFN- and IL-2 (9–12).
The molecule BIM seems to be the mayor intracellular player in
the connection of the apoptotic pathway to the mitochondria
(13). Our hypothesis is that ICAM-2, when cross-linked with the
antibody, sets in motion a signaling pathway that interferes with
these cascades. Anti-CD137 mAbs may exert a similar type of
effect leading also to effective tumor immunity (46, 47).
Alternatively or complementarily, EOL4G8 mAb has been
shown to enhance the avidity of the ICAM-2/DC-SIGN inter-
action (6). This would provide the therapeutic antibody with the
opportunity to enhance the immune response by acting on the
synapse formed by preactivated T cells and dendritic cells. In
this regard, we have preliminary evidence showing that ICAM-2
is located in the T-cell/APC contact area in an early and antigen-
independent fashion.5
In conclusion, we herein describe an efficacious combined
strategy for cancer treatment encompassing IL-12 intratumoral
gene transfer and systemic anti-ICAM-2 antibody treatment that
requires caution because it can result in lethal toxicity. Both the
efficacy and the late-onset toxicity are probably related to the
ability of the anti-ICAM-2 mAbs to prevent the AICD of T
lymphocytes, thus extending the effector time of IFN--produc-
ing CTLs.
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